Abstract
An investigation was made on the therapeutic effect of Glybenclamide (HB 419), a new oral anti-diabetic drug, and also on the changes in the blood IRI reac tion after glucose administration during the course of treatment with the drug.
Results were as follows:
1) HB 419, 5-10mg. was administered once daily after breakfast to 53cases of diabetes. Good control was obtained in 32cases (62%), fair control in 7cases (14%), primary failure in 12cases (24%), and of the remaining 2cases one case was a secondary failure and evaluation was not clear in the other case.
2) The therapeutic effect of HB 419is influenced by the type of diabetes mellitus, i. e., the drug is usually ineffective in juvenile and generally lean patients. The effect of the drug is unrelated to the severity of the disease as seen from the viewpoint of the fasting blood sugar level. The drug is more effective in non-treated cases than in cases which have received previous treatment. The drug lowers fasting blood sugar level, however, it does not completely normalize the glucose tolerance curve.
3) No serious side effect due to the drug has been observed, however, routine clinical examinations should not be neglected during use of the drug in order to detect any early sign of side effects.
4) The relation between glucose tolerance and IRI reaction was studied over a period of 12months, result of which was as follows: In 13non-obese cases IRI reaction tended to become normal with improvement of glucose tolerance.
From the aforementioned results it is thought that the drug not only stimulates the β cells of the islands of Langerhans, but also has extra-pancreatic action such as that on the liver, or on adipose and muscle tissues, or that on insulin antagonism or on the modality of the presence of insulin in the blood.
